GILD (Gilead Sciences, Inc.) Utang jangka cendhak marang modal

Gilead Sciences, Inc. (GILD) relies on stable demand in HIV therapy, which offsets macroeconomic risks. The trend of short-term liabilities to equity visualizes the current load, where the value of 0.18 reflects this status. The scalability of the model ensures high margins with low costs. High barriers to entry and patent protection guarantee the company a monopoly position in the market.

For Gilead Sciences, Inc. (GILD), which invests in oncology and cell therapy, the current trend of short-term liabilities to equity reflects a balance between the aggressive acquisition of biotech startups and financial stability. This metric measures the proportion of obligations maturing within one year relative to shareholders' equity. The calculation identifies the business's reliance on the rapid refinancing of current debts. An increase in this ratio signals liquidity risks, while its minimum confirms a conservative approach to resource management.